Cargando…

Active Ratio Test (ART) as a Novel Diagnostic for Ovarian Cancer

Background: Despite substantial effort, there remains a lack of biomarker-based, clinically relevant testing for the accurate, non-invasive diagnostic or prognostic profiling of epithelial ovarian cancers (EOC). Our previous work demonstrated that whilst the inflammatory marker C-X-C motif chemokine...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Sung-Woog, Rainczuk, Adam, Oehler, Martin K., Jobling, Thomas W., Plebanski, Magdalena, Stephens, Andrew N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230042/
https://www.ncbi.nlm.nih.gov/pubmed/34200333
http://dx.doi.org/10.3390/diagnostics11061048
_version_ 1783713113824034816
author Kang, Sung-Woog
Rainczuk, Adam
Oehler, Martin K.
Jobling, Thomas W.
Plebanski, Magdalena
Stephens, Andrew N.
author_facet Kang, Sung-Woog
Rainczuk, Adam
Oehler, Martin K.
Jobling, Thomas W.
Plebanski, Magdalena
Stephens, Andrew N.
author_sort Kang, Sung-Woog
collection PubMed
description Background: Despite substantial effort, there remains a lack of biomarker-based, clinically relevant testing for the accurate, non-invasive diagnostic or prognostic profiling of epithelial ovarian cancers (EOC). Our previous work demonstrated that whilst the inflammatory marker C-X-C motif chemokine ligand 10 (CXCL10) has prognostic relevance in ovarian cancer, its use is complicated by the presence of multiple, N-terminally modified variants, mediated by several enzymes including Dipeptidyl Peptidase 4 (DPP4). Methods: In this study, we provide the first evidence for the “Active Ratio Test” (ART) as a novel method to measure biologically relevant CXCL10 proteoforms in clinical samples. Results: In a cohort of 275 patients, ART accurately differentiated patients with malignant EOCs from those with benign gynaecological conditions (AUC 0.8617) and significantly out-performed CA125 alone. Moreover, ART combined with the measurement of CA125 and DPP4 significantly increased prognostic performance (AUC 0.9511; sensitivity 90.0%; specificity 91.7%; Cohen’s d > 1) for EOC detection. Conclusion: Our data demonstrate that ART provides a useful method to accurately discriminate between patients with benign versus malignant EOC, and highlights their relevance to ovarian cancer diagnosis. This marker combination may also be applicable in broader screening applications, to identify or discriminate benign from malignant disease in asymptomatic women.
format Online
Article
Text
id pubmed-8230042
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82300422021-06-26 Active Ratio Test (ART) as a Novel Diagnostic for Ovarian Cancer Kang, Sung-Woog Rainczuk, Adam Oehler, Martin K. Jobling, Thomas W. Plebanski, Magdalena Stephens, Andrew N. Diagnostics (Basel) Article Background: Despite substantial effort, there remains a lack of biomarker-based, clinically relevant testing for the accurate, non-invasive diagnostic or prognostic profiling of epithelial ovarian cancers (EOC). Our previous work demonstrated that whilst the inflammatory marker C-X-C motif chemokine ligand 10 (CXCL10) has prognostic relevance in ovarian cancer, its use is complicated by the presence of multiple, N-terminally modified variants, mediated by several enzymes including Dipeptidyl Peptidase 4 (DPP4). Methods: In this study, we provide the first evidence for the “Active Ratio Test” (ART) as a novel method to measure biologically relevant CXCL10 proteoforms in clinical samples. Results: In a cohort of 275 patients, ART accurately differentiated patients with malignant EOCs from those with benign gynaecological conditions (AUC 0.8617) and significantly out-performed CA125 alone. Moreover, ART combined with the measurement of CA125 and DPP4 significantly increased prognostic performance (AUC 0.9511; sensitivity 90.0%; specificity 91.7%; Cohen’s d > 1) for EOC detection. Conclusion: Our data demonstrate that ART provides a useful method to accurately discriminate between patients with benign versus malignant EOC, and highlights their relevance to ovarian cancer diagnosis. This marker combination may also be applicable in broader screening applications, to identify or discriminate benign from malignant disease in asymptomatic women. MDPI 2021-06-07 /pmc/articles/PMC8230042/ /pubmed/34200333 http://dx.doi.org/10.3390/diagnostics11061048 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kang, Sung-Woog
Rainczuk, Adam
Oehler, Martin K.
Jobling, Thomas W.
Plebanski, Magdalena
Stephens, Andrew N.
Active Ratio Test (ART) as a Novel Diagnostic for Ovarian Cancer
title Active Ratio Test (ART) as a Novel Diagnostic for Ovarian Cancer
title_full Active Ratio Test (ART) as a Novel Diagnostic for Ovarian Cancer
title_fullStr Active Ratio Test (ART) as a Novel Diagnostic for Ovarian Cancer
title_full_unstemmed Active Ratio Test (ART) as a Novel Diagnostic for Ovarian Cancer
title_short Active Ratio Test (ART) as a Novel Diagnostic for Ovarian Cancer
title_sort active ratio test (art) as a novel diagnostic for ovarian cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230042/
https://www.ncbi.nlm.nih.gov/pubmed/34200333
http://dx.doi.org/10.3390/diagnostics11061048
work_keys_str_mv AT kangsungwoog activeratiotestartasanoveldiagnosticforovariancancer
AT rainczukadam activeratiotestartasanoveldiagnosticforovariancancer
AT oehlermartink activeratiotestartasanoveldiagnosticforovariancancer
AT joblingthomasw activeratiotestartasanoveldiagnosticforovariancancer
AT plebanskimagdalena activeratiotestartasanoveldiagnosticforovariancancer
AT stephensandrewn activeratiotestartasanoveldiagnosticforovariancancer